Current and Soon-to-Be-Approved Regimens Offer High Cure Rates for HCV.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 30, doi. 10.1177/155989771448022
- By:
- Publication type:
- Article
Works matching IS 15598977 AND DT 2014 AND VI 14 AND IP 48
Results: 22
1
2
Accurate Diagnosis and Appropriate Treatment Beneficial for HRS and AIH.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 28, doi. 10.1177/155989771448021
- By:
- Publication type:
- Article
3
New Treatments for Hepatitis C.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 26, doi. 10.1177/155989771448020
- By:
- Publication type:
- Article
4
Interferon- and RBV-Free Treatment with LDV and SOF is Efficacious in Patients Coinfected with HCV and HIV.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 25, doi. 10.1177/155989771448019
- By:
- Publication type:
- Article
5
High Efficacy Rates with Grazoprevir Plus Elbasvir in HCV Monoinfection and HCV/HIV Coinfection.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 23, doi. 10.1177/155989771448018
- By:
- Publication type:
- Article
6
100% SVR with Ledipasvir/Sofosbuvir Plus Ribavirin in Patients with HCV GT-1 Failing Prior Therapy.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 22, doi. 10.1177/155989771448017
- By:
- Publication type:
- Article
7
HCV—Infected Patients with Compensated Cirrhosis Benefit from 12-Week, Once-Daily, Oral Combination of LDV and SOF.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 21, doi. 10.1177/155989771448016
- By:
- Publication type:
- Article
8
SVR after Treatment of HCV Genotype 1a with ABT-450/Ritonavir, Ombitasvir, and Dasabuvir is Enhanced by RBV in Noncirrhotic Patients and by Extension of Duration in Cirrhotic Patients.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 20, doi. 10.1177/155989771448015
- By:
- Publication type:
- Article
9
Myrcludex B Therapy Reduced HBV DNA and HDV RNA in Phase 2a Clinical Trial.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 19, doi. 10.1177/155989771448014
- By:
- Publication type:
- Article
10
Direct-Acting Antiviral Therapy Produces High SVR12 in HCV GT-1 Cirrhotic Patients Regardless of Baseline Characteristics.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 18, doi. 10.1177/155989771448013
- By:
- Publication type:
- Article
11
Terlipressin and Albumin Combination Therapy Improves Renal Function in HRS-1.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 17, doi. 10.1177/155989771448012
- By:
- Publication type:
- Article
12
SOF Plus GS-5816 Effective in Noncirrhotic, Treatment-Naïve Patients Infected with HCV Genotypes 1 to 6.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 17, doi. 10.1177/155989771448011
- By:
- Publication type:
- Article
13
Uniform Downstaging Protocol Produces Excellent Posttransplantation Outcomes in HCC.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 16, doi. 10.1177/155989771448010
- By:
- Publication type:
- Article
14
Sustained Virologic Response of 91% in Patients Infected with HCV Treated with DCV-TRIO.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 15, doi. 10.1177/155989771448009
- By:
- Publication type:
- Article
15
Sebelipase Alfa Normalizes ALT and Multiple other Disease-Related Abnormalities in Patients with LAL-D.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 14, doi. 10.1177/155989771448008
- By:
- Publication type:
- Article
16
SOF Plus GS-5816 Effective in Noncirrhotic Patients Infected with HCV GT-3: ELECTRON-2 Final Results.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 13, doi. 10.1177/155989771448007
- By:
- Publication type:
- Article
17
Combination DCV/SOF is Effective in Achieving Sustained Response in Patients with HCV GT-3.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 12, doi. 10.1177/155989771448006
- By:
- Publication type:
- Article
18
Prednisolone but Not PTX Improves 28-Day Mortality in Patients with Alcoholic Hepatitis.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 10, doi. 10.1177/155989771448004
- By:
- Publication type:
- Article
19
Rapid Sustained HCV Viral Load Reductions Achieved with ACH-3102 Plus SOF.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 9, doi. 10.1177/155989771448003
- By:
- Publication type:
- Article
20
Use of Molecular Biology for Identifying Benign Hepatocellular Tumors Leads to More Personalized Medicine.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 6, doi. 10.1177/155989771448002
- By:
- Publication type:
- Article
21
Current Perspectives on LDLT.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 4, doi. 10.1177/155989771448001
- By:
- Publication type:
- Article
22
DCV/ASV/BCV Improves Sustained Viral Response in Patients with Chronic HCV GT-1 Infection and Compensated Cirrhosis: UNITY-2 Results.
- Published in:
- MD Conference Express, 2014, v. 14, n. 48, p. 11, doi. 10.1177/155989771448005
- By:
- Publication type:
- Article